KapsimaliVDKanakisMAVaiopoulosGAKaklamanisPG. Etiopathogenesis of Behçet’s disease with emphasis on the role of immunological aberrations. Clin Rheumatol. 2010;29(11):1211–1216.
5.
BaltaIBaltaSKoryurekOM. Mean platelet volume is associated with aortic arterial stiffness in patients with Behçet’s disease without significant cardiovascular involvement [published online October 25, 2013]. J Eur Acad Dermatol Venereol. 2013.
6.
EhrlichGE. Vasculitis in Behçet’s disease. Int Rev Immunol. 1997;14(1):81–88.
7.
EkizOBaltaISenBB. Mean platelet volume in recurrent aphthous stomatitis and Behcet disease. Angiology. 2014;65(2):161–165.
8.
BaltaSDemirkolSCelikT. Association between coronary artery ectasia and neutrophil-lymphocyte ratio. Angiology. 2013;64(8):627–632.
9.
DemirkolSBaltaSCelikT. Assessment of the relationship between red cell distribution width and cardiac syndrome X. Kardiol Pol. 2013;71(5):480–484.
10.
CakarMBaltaSDemirkolSAltunBDemirbasS. Serum gamma-glutamyltransferase (GGT) should be evaluated together with other inflammatory markers in clinical practice. Angiology. 2013;64(5):401.
11.
CakarMSarlakHBaltaSUnluMDemirbasSDemirkolS. Serum uric acid still carries controversies about its role in endothelial dysfunction. J Clin Hypertens (Greenwich). 2013;15(4):296.
12.
BaltaSCakarMDemirkolSArslanZAkhanM. Higher neutrophil to lymhocyte ratio in patients with metabolic syndrome. Clin Appl Thromb Hemost. 2013;19(5):579.
13.
BaltaSDemirkolSKucukUSarlakHKurtOArslanZ. Neutrophil to lymphocyte ratio may predict mortality in breast cancer patients. J Breast Cancer. 2013;16(3):354–355.
14.
AltunBBulucuFDemirbasS. The relationship between some of the cardiovascular risk factors and arterial stiffness parameters in essentially hypertensive patients. Clin Exp Hypertens. 2013;35(6):444–448.
15.
DemirkolSBaltaSCelikT. Carotid intima media thickness and its association with total bilirubin levels in patients with coronary artery ectasia [published online on January 28, 2013]. Angiology. 2013. doi: 10.1177/0003319712473796.
16.
UnluMKaramanMAySA. The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients. Clin Exp Hypertens. 2013;35(6):418–423.
17.
BaltaIBaltaSKoryurekOM. Serum endocan levels as a marker of disease activity in patients with Behçet’s disease [published online October 28, 2013]. J Am Acad Dermatol. 2013.
18.
OflazHMercanogluFKaramanO. Impaired endothelium-dependent flow-mediated dilation in Behçet’s disease: more prominent endothelial dysfunction in patients with vascular involvement. Int J Clin Pract. 2005;59(7):777–781.
19.
KayikçioğluMAksuKHasdemirC. Endothelial functions in Behçet’s disease. Rheumatol Int. 2006;26(4):304–308.
20.
OzdemirRBarutcuISezginAT. Vascular endothelial function and plasma homocysteine levels in Behcet’s disease. Am J Cardiol. 2004;94(4):522–525.
21.
CekmenMEverekliogluCErH. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet’s syndrome. Int J Dermatol. 2003;42(11):870–875.
22.
HaznedarogluEKaraaslanYBüyükaşikY. Selectin adhesion molecules in Behçet’s disease. Ann Rheum Dis. 2000;59(1):61–63.
23.
KosarAHaznedarogluSKaraaslanY. Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet’s disease. Rheumatol Int. 1999;19(1-2):11–14.
24.
OztürkMAUnverdiSOktarSO. Vascular endothelial growth factor and carotid intima-media thickness in patients with Behçet’s disease. Clin Rheumatol. 2008;27(8):961–966.
25.
KirazSErtenliIOztürkMAHaznedaroğluICCelikICalgüneriM. Pathological haemostasis and “prothrombotic state” in Behçet’s disease. Thromb Res. 2002;105(2):125–133.
26.
OremAGCimşitDeğerOVanizorBKarahanSC. Autoantibodies against oxidatively modified low-density lipoprotein in patients with Behçet’s disease. Dermatology. 1999;198(3):243–246.
27.
EverekliogluCTurkozYErHInalozHSOzbekECekmenM. Increased nitric oxide production in patients with Behçet’s disease: is it a new activity marker?J Am Acad Dermatol. 2002;46(1):50–54.
SahinMArslanC. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet’s disease. Ann Clin Lab Sci. 2006;36(4):449–454.
30.
MarumoTSchini-KerthVBBusseR. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes. 1999;48(5):1131–1137.
31.
ChambersJCHaskardDOKoonerJS. Vascular endothelial function and oxidative stress mechanisms in patients with Behçet’s syndrome. J Am Coll Cardiol. 2001;37(2):517–520.
32.
BaltaIBaltaSDemirkolS. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169(5):1066–1070.
33.
OzoguzPKarabulutAATulmacMKisaUKocakMGunduzO. Markers of endothelial dysfunction and evaluation of vascular reactivity tests in behçet’s disease [published online on November 25, 2013]. Angiology. 2013. doi: 10.1177/0003319713512413.
